<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Baxter International</title>
	<atom:link href="http://www.stockbloghub.com/tag/baxter-international/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Mon, 21 May 2012 16:42:30 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(HSP) Hospira Ups 2009 Guidance</title>
		<link>http://www.stockbloghub.com/2009/09/18/hsp-hospira-ups-2009-guidance/15635</link>
		<comments>http://www.stockbloghub.com/2009/09/18/hsp-hospira-ups-2009-guidance/15635#comments</comments>
		<pubDate>Fri, 18 Sep 2009 23:56:14 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Featured]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15635</guid>
		<description><![CDATA[Lake Forest, Illinois-based specialty pharmaceutical products maker Hospira (HSP) recently raised its 2009 outlook. The company now sees earnings in the range of $2.80 to $2.85 per share up from its earlier guidance of $2.70 to $2.75. Annual revenue is expected to rise by 5 to 7% compared to the earlier expected growth of 4 to 6% on a constant currency basis. Hospira also boosted its 2009 outlook for gross margin, operating margin and cash flow from operations to 39.5%-40.5%, 18%-19% and $610 million-$660 million, respectively. Hospira said it was confident that its cost cutting and restructuring initiative, Project Fuel, would improve profitability through 2011. The company’s restructuring plan consists of a 10% reduction in workforce and realignment of its product portfolio including the sale of non-core businesses. It has ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/18/hsp-hospira-ups-2009-guidance/15635/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BAX) Baxter International Discussed Long-Term Goals</title>
		<link>http://www.stockbloghub.com/2009/09/18/bax-baxter-international-discussed-long-term-goals/15632</link>
		<comments>http://www.stockbloghub.com/2009/09/18/bax-baxter-international-discussed-long-term-goals/15632#comments</comments>
		<pubDate>Fri, 18 Sep 2009 23:53:47 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton]]></category>
		<category><![CDATA[Dickinson And Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15632</guid>
		<description><![CDATA[Baxter International Inc. (BAX) discussed its long-term financial objectives, growth opportunities and various research and development (R&#38;D) programs at its recently concluded Investor Conference in Chicago. The long-term (5-year) financial objectives are as follows: Increase sales roughly 7% to 8% per annum, excluding foreign exchange translation effect Grow earnings per share in the range of 11% to 13% per annum Generate annual cash flow of approximately $4 billion by 2014 Baxter also plans to expand its strong existing product portfolio by enhancing R&#38;D investments at a compound annual rate of a minimum 8% to 10% from 7% at the end of fiscal 2008. The company will continue to hunt for business development opportunities through its disciplined acquisition strategy. We are confident that Baxter will be able to deliver on its ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/18/bax-baxter-international-discussed-long-term-goals/15632/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HAE) Haemonetics Corporation Inks Software Deal</title>
		<link>http://www.stockbloghub.com/2009/09/18/hae-haemonetics-corporation-inks-software-deal/15664</link>
		<comments>http://www.stockbloghub.com/2009/09/18/hae-haemonetics-corporation-inks-software-deal/15664#comments</comments>
		<pubDate>Fri, 18 Sep 2009 23:36:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corp]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15664</guid>
		<description><![CDATA[Haemonetics Corp. (HAE) yesterday announced that it has entered into a deal with Blood Centers of America Inc. (“BCA&#8221;), a cooperative of community blood centers, which will provide BCA members access to Haemonetics’ blood management software. Specifically, the agreement provides the BCA member’s access to Prelude and Interlude, modules of Haemonetics&#8217; integrated Symphony set of products that are designed to automate blood bank operations. Furthermore, BCA members will also have access to Haemonetics’ eQue automated interview and assessment donor screening system. The eQue automated interview and assessment donor screening system is a donor registration and assessment tool designed to assist blood banks and plasma centers in determining a person’s eligibility to donate blood. We feel that this deal will benefit BCA members in a significant manner and will enhance the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/18/hae-haemonetics-corporation-inks-software-deal/15664/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BAX) Top Health Equity Funds &#8211; Mutual Fund Commentary</title>
		<link>http://www.stockbloghub.com/2009/09/16/bax-top-health-equity-funds-mutual-fund-commentary/15296</link>
		<comments>http://www.stockbloghub.com/2009/09/16/bax-top-health-equity-funds-mutual-fund-commentary/15296#comments</comments>
		<pubDate>Wed, 16 Sep 2009 17:06:35 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International]]></category>
		<category><![CDATA[COV]]></category>
		<category><![CDATA[Covidien]]></category>
		<category><![CDATA[Limited]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15296</guid>
		<description><![CDATA[Today we are featuring top-performing “Health&#8221; equity mutual funds, which primarily invest in equity securities of healthcare and related companies. Investors can find such funds by checking out the entire list of the Zacks #1 Rank Health Equity Funds. 3 Robust Samples Fidelity Select Medical Equipment &#38; Systems (FSMEX) was incepted in April 1998. The investment seeks capital appreciation by investing in securities of healthcare companies. The fund may invest in securities of foreign issuers and invest a significant percentage of assets in a single issuer. It is non-diversified. The fund’s top holdings include Baxter International Inc. (BAX), Covidien Ltd. (COV) and Medtronic Inc. (MDT). Evergreen Health Care A (EHABX) seeks long-term capital growth. It primarily invests in equity securities of issuers that derive more than 50% of their sales ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/16/bax-top-health-equity-funds-mutual-fund-commentary/15296/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BAX) Baxter International Fails to Deliver Swine Flu Vaccine</title>
		<link>http://www.stockbloghub.com/2009/09/16/bax-baxter-international-fails-to-deliver-swine-flu-vaccine/15253</link>
		<comments>http://www.stockbloghub.com/2009/09/16/bax-baxter-international-fails-to-deliver-swine-flu-vaccine/15253#comments</comments>
		<pubDate>Wed, 16 Sep 2009 16:31:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton]]></category>
		<category><![CDATA[Dickinson And Company]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15253</guid>
		<description><![CDATA[Baxter International Inc. (BAX) has failed to deliver on its pledge to the U.K. government to supply required quantities of swine flu vaccine, Celvapan. The company has supplied only half of the 400,000 doses of Celvapan it had agreed to supply by the end of Aug 2009. Britain’s Department of Health allocated Baxter 30 million of the 90 million doses of a $745 million (?450 million) contract placed in May 2009. The remaining 60 million doses were allocated to GlaxoSmithKline plc (GSK). Baxter has already received contracts from five governments Incorporatedluding the Governments of Ireland and New Zealand, for 80 million doses of swine flu vaccines. The company has decided not to sign any more contracts since it is already running behind schedule. The U.K. government is working with Baxter ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/16/bax-baxter-international-fails-to-deliver-swine-flu-vaccine/15253/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HAE) Haemonetics Corporation Acquires Engineering and Research Associates Inc</title>
		<link>http://www.stockbloghub.com/2009/09/09/hae-haemonetics-corporation-acquires-engineering-and-research-associates-inc/14711</link>
		<comments>http://www.stockbloghub.com/2009/09/09/hae-haemonetics-corporation-acquires-engineering-and-research-associates-inc/14711#comments</comments>
		<pubDate>Wed, 09 Sep 2009 21:56:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corp]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14711</guid>
		<description><![CDATA[Haemonetics Corporation (HAE) has recently acquired the blood collection and processing business of Engineering and Research Associates Inc., commonly known as SEBRA. The transaction is worth $12.5 million in cash and is expected to be completed in a few months time. The SEBRA acquisition expands the vista of Haemonetics’ product offerings and increases its top-line. Furthermore, it strengthens the company’s position in the whole blood collection market. Haemonetics is developing an automated whole blood collection system and expects to launch it in late fiscal 2011. The SEBRA acquisition is expected to be neutral to Haemonetics’ earnings per share in fiscal 2010 and accretive thereafter. SEBRA markets a suite of products such as radio-frequency tube sealers, whole blood collection devices known as shakers, and mobile collection &#38; ancillary equipment. These products ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/09/hae-haemonetics-corporation-acquires-engineering-and-research-associates-inc/14711/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SNY) Sanofi Grows Strong on Vaccines</title>
		<link>http://www.stockbloghub.com/2009/09/08/sny-sanofi-grows-strong-on-vaccines/14647</link>
		<comments>http://www.stockbloghub.com/2009/09/08/sny-sanofi-grows-strong-on-vaccines/14647#comments</comments>
		<pubDate>Wed, 09 Sep 2009 00:06:09 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14647</guid>
		<description><![CDATA[We are pleased to hear that India’s Shantha Biotechnics received a $340 million contract to supply its combination vaccine, SHAN5 for the period of 2010-2012 from a United Nations agency. The vaccine is used for immunizing children against five diseases &#8211; Diptheria, Tetanus, Pertussis, Hepatitis B and Hemophilus Influenza B. In July, Sanofi-Aventis’ (SNY) vaccine division Sanofi Pasteur had acquired a 78% stake in Shantha Biotechnics for 550 million Euros ($783 million). Shantha Biotech has been a prominent player in the vaccine segment for quite some time. It works with several international agencies like the UNICEF in the Asia Pacific, Africa and Latin America. The company is expected to post sales of $90 million in 2009. The deal should be beneficial to both the companies. While Shantha Biotechnics has the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/08/sny-sanofi-grows-strong-on-vaccines/14647/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BDX) Becton, Dickinson and Company Receives $52 Million Government Order</title>
		<link>http://www.stockbloghub.com/2009/09/04/bdx-becton-receives-52-million-government-order/14486</link>
		<comments>http://www.stockbloghub.com/2009/09/04/bdx-becton-receives-52-million-government-order/14486#comments</comments>
		<pubDate>Fri, 04 Sep 2009 22:15:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton]]></category>
		<category><![CDATA[Dickinson And Company]]></category>
		<category><![CDATA[Harte-Hanks Inc.]]></category>
		<category><![CDATA[HHS]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14486</guid>
		<description><![CDATA[Becton, Dickinson and Company (BDX) received an order from the Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Department of Health and Human Services (HHS) for the purchase of syringes and needles, sharps collectors and alcohol swabs for use in national flu pandemic preparedness efforts. The order, worth approximately $52 million, is effective through March 2010. The new contract is part of the company’s effort to protect Americans from the H1N1 influenza virus, commonly known as &#8220;swine flu.&#8221; Becton is also in constant touch with governments and vaccine companies across the globe to meet their needs during the flu season. We think that the new contract will boost Becton’s top-line. This will also add to the company’s contribution to social welfare. Becton, Dickinson and Co. develops, manufactures and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/04/bdx-becton-receives-52-million-government-order/14486/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) Top Health Equity Mutual Funds</title>
		<link>http://www.stockbloghub.com/2009/09/02/mdt-top-health-equity-mutual-funds/14159</link>
		<comments>http://www.stockbloghub.com/2009/09/02/mdt-top-health-equity-mutual-funds/14159#comments</comments>
		<pubDate>Wed, 02 Sep 2009 20:21:37 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[Incorporated]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14159</guid>
		<description><![CDATA[Today we are featuring top-performing “Health&#8221; equity mutual funds, which primarily invest in equity securities of health care and related companies. Investors can find such funds by checking out the entire list of the Zacks #1 Rank Health Equity Funds. 3 Robust Samples Fidelity Select Medical Equipment &#38; Systems (FSMEX) seeks capital appreciation. The fund is non-diversified. The fund invests in common stocks of firms that are engaged in research, development, manufacture, distribution, supply or sale of medical equipment and devices and related technologies. It may invest in securities of foreign issuers or a significant percentage of assets in a single issuer. The fund’s key holdings include Medtronic Inc. (MDT), Baxter International Inc. (BAX) and Boston Scientific Inc. (BSX). Evergreen Health Care A (EHABX) was incepted in December 1999. The ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/02/mdt-top-health-equity-mutual-funds/14159/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AZN) Almost 25 Pharmaceutical Companies are Racing to Bring H1N1the Vaccine to Market</title>
		<link>http://www.stockbloghub.com/2009/08/25/azn-almost-25-pharmaceutical-companies-are-racing-to-bring-h1n1the-vaccine-to-market/13344</link>
		<comments>http://www.stockbloghub.com/2009/08/25/azn-almost-25-pharmaceutical-companies-are-racing-to-bring-h1n1the-vaccine-to-market/13344#comments</comments>
		<pubDate>Tue, 25 Aug 2009 20:57:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13344</guid>
		<description><![CDATA[Although we are waiting eagerly for the first H1N1 vaccine to hit the market, it seems production of the vaccine will be much less than the original estimates. According to a warning from the World Health Organization (WHO), supply will be much less than anticipated earlier, especially with the winter season approaching in the northern hemisphere. Per initial estimates from October onwards, about 94 million doses of vaccine could have been manufactured by the pharmaceutical companies, but this target has already been slashed by 50-75% due to poorer than expected yield from the virus strains. Almost 25 pharmaceutical companies are racing against time to bring the vaccine to the market. Among these the top five which include, Sanofi-Pasteur of France (the vaccine arm of Sanofi-Aventis, SNY), AstraZeneca (AZN), GlaxoSmithKline (GSK), ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/25/azn-almost-25-pharmaceutical-companies-are-racing-to-bring-h1n1the-vaccine-to-market/13344/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>($BAX) Baxter International &#8211; ROE of 35%, soaring past the industry average of 8%$</title>
		<link>http://www.stockbloghub.com/2009/07/23/bax-baxter-international-upped-its-full-year-earnings-guidance/11132</link>
		<comments>http://www.stockbloghub.com/2009/07/23/bax-baxter-international-upped-its-full-year-earnings-guidance/11132#comments</comments>
		<pubDate>Thu, 23 Jul 2009 18:55:38 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=11132</guid>
		<description><![CDATA[Baxter International Inc. (BAX) recently posted second-quarter earnings of 96 cents per share, topping the consensus estimate by 2% and surpassing the previous year&#8217;s 85 cents. The company also upped its full-year earnings guidance, and analysts followed suit. Company Description Baxter International develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, cancer, infectious diseases, kidney disease, trauma and other chronic and acute medical conditions. As a global diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. The company&#8217;s products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors&#8217; offices, clinical and medical research laboratories, and by patients at home under physician supervision. Baxter manufactures ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/07/23/bax-baxter-international-upped-its-full-year-earnings-guidance/11132/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BAX) Medical Devices &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2009/07/14/bax-medical-devices-industry-outlook/10016</link>
		<comments>http://www.stockbloghub.com/2009/07/14/bax-medical-devices-industry-outlook/10016#comments</comments>
		<pubDate>Wed, 15 Jul 2009 01:03:57 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson And Company]]></category>
		<category><![CDATA[Merge Healthcare Incorporated.]]></category>
		<category><![CDATA[MRGE]]></category>
		<category><![CDATA[OMCL]]></category>
		<category><![CDATA[Omnicell Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=10016</guid>
		<description><![CDATA[Since the beginning of the global economic crisis, medical device stocks have fared slightly worse than the overall market, losing roughly 400 bps more than the S&#38;P500 (-31%) since September 1, 2008, on a market weighted basis. We continue to recommend that investors focus on companies providing life-sustaining products. We believe these products will remain insulated from the longer-term effects of the current economic crisis because target patients will be unable to forego procedures. The initial slide in the market left many strong companies looking very attractive. In the coming year, investors should allocate funds to companies with high earnings quality profiles. We recommend companies with the following characteristics: Size – (1) Larger companies will find it easier to survive any future liquidity issues and acquire new technologies at cents on the dollar.  ?(2) Size also ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/07/14/bax-medical-devices-industry-outlook/10016/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BAX) Baxter International Inc. &#8211; Growth And Income &#8211; Zacks Rank Buy</title>
		<link>http://www.stockbloghub.com/2009/06/23/bax-baxter-international-inc-growth-and-income-zacks-rank-buy-2/8770</link>
		<comments>http://www.stockbloghub.com/2009/06/23/bax-baxter-international-inc-growth-and-income-zacks-rank-buy-2/8770#comments</comments>
		<pubDate>Tue, 23 Jun 2009 22:00:26 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=8770</guid>
		<description><![CDATA[Baxter International Inc. (BAX) is seeing upbeat estimates ahead of announcing second-quarter results in early July. Analysts are calling for full-year earnings of $3.77 per share, an upward revision of 2 cents over the past 3 months. Company Description Baxter International develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, cancer, infectious diseases, kidney disease, trauma and other chronic and acute medical conditions. As a global diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. The company&#8217;s products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors&#8217; offices, clinical and medical research laboratories, and by patients at home under physician supervision. Baxter manufactures products ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/06/23/bax-baxter-international-inc-growth-and-income-zacks-rank-buy-2/8770/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BAX) Baxter International, Inc.  &#8211; Growth And Income &#8211; Zacks Rank Buy</title>
		<link>http://www.stockbloghub.com/2009/02/27/bax-baxter-international-inc-growth-and-income-zacks-rank-buy/3763</link>
		<comments>http://www.stockbloghub.com/2009/02/27/bax-baxter-international-inc-growth-and-income-zacks-rank-buy/3763#comments</comments>
		<pubDate>Fri, 27 Feb 2009 22:44:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=3763</guid>
		<description><![CDATA[Baxter International Inc. (BAX) recently declared a quarterly dividend of 26 cents per share, noting that it is payable on April 1 to shareholders of record as of the close of business on March 10. Company Description Baxter International develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, cancer, infectious diseases, kidney disease, trauma and other chronic and acute medical conditions. As a global diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. The company&#8217;s products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors&#8217; offices, clinical and medical research laboratories, and by patients at home under physician supervision. Baxter manufactures products in 26 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/02/27/bax-baxter-international-inc-growth-and-income-zacks-rank-buy/3763/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BAX) Baxter International &#8211; ROE of 31% more than doubles the industry average of 12%</title>
		<link>http://www.stockbloghub.com/2009/02/09/baxter-international-roe-of-31-more-than-doubles-the-industry-average-of-12/2612</link>
		<comments>http://www.stockbloghub.com/2009/02/09/baxter-international-roe-of-31-more-than-doubles-the-industry-average-of-12/2612#comments</comments>
		<pubDate>Mon, 09 Feb 2009 22:27:32 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International]]></category>
		<category><![CDATA[VitalStocks]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=2612</guid>
		<description><![CDATA[Baxter International Inc. (BAX) recently reported record results for 2008, surpassing its guidance. The company also sees double-digit earnings growth in 2009. Company Description Baxter International develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, cancer, infectious diseases, kidney disease, trauma and other chronic and acute medical conditions. As a global diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. The company’s products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices, clinical and medical research laboratories, and by patients at home under physician supervision. Baxter manufactures products in 26 countries and sells them in more than 100 countries. Quarterly Report Shows Record ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/02/09/baxter-international-roe-of-31-more-than-doubles-the-industry-average-of-12/2612/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

